HomeSearchGlobal LocationsContact UsGenzyme Websites
About GenzymeOur ResearchOur ProductsOur Commitment
Genzyme

Corporate Info
Investors
News
Investor Events
Financial Reports
Guidance and Reconciliation
Research Pipeline
Analyst Coverage
Corporate Governance
Frequently Asked Questions
News
Partnering
Genzyme Events
Careers
Global Locations

News

Genzyme Releases

inv_genz_news_all Genzyme General News
November 18, 2009 Genzyme Announces Results of Phase 2/3 Trial of Advanced Phosphate Binder
November 17, 2009 Data from Mipomersen Phase 3 Trial in hoFH Patients Presented at AHA
November 16, 2009 Genzyme Receives Complete Response Letter on Lumizyme Application
November 13, 2009 Genzyme Issues Letters to U.S. Healthcare Providers
October 21, 2009 Genzyme Reports Third-Quarter Financial Results
October 20, 2009 First Patient Enrolled in Phase 3 Trials of Genzyme Oral Capsule for Gaucher Disease
October 14, 2009 Scientists Name Genzyme a Top Employer
October 6, 2009 Genzyme Receives FDA Complete Response Letter for Clolar
October 2, 2009 Genzyme Named to Dow Jones Sustainability World and North American Indexes
September 24, 2009 Genzyme’s Campath Meets Primary Endpoint in Phase 3 Combination Therapy Trial for Chronic Lymphocytic Leukemia
September 23, 2009 Genzyme Provides Update on Cerezyme and Fabrazyme Supply
September 11, 2009 Genzyme’s Alemtuzumab for Multiple Sclerosis Shows Durable Treatment Benefit in Review of Four-Year Phase 2 Trial Data
September 01, 2009 FDA Advisory Committee Recommends Randomized Trial to Support Proposed Indication for Clolar in Adult AML
August 28, 2009 FDA Advisory Committee to Discuss Genzyme’s Clolar for Adult AML on Sept. 1
August 10, 2009 Genzyme Provides Update on Cerezyme Supply and 2009 Financial Information
August 5, 2009 European Commission Approves Genzyme’s Mozobil
July 31, 2009 Genzyme Provides Update on Allston Landing Plant
July 22, 2009 Genzyme Delivers Solid Second-Quarter Financial Results
June 25, 2009 Genzyme Reports Progress Related to Allston Plant
June 16, 2009 Genzyme Temporarily Interrupts Production at Allston Plant
June 12, 2009 Genzyme Receives European Approval of Renvela for Patients with Chronic Kidney Disease
June 2, 2009 Genzyme Completes Transaction with Bayer HealthCare
May 29, 2009 Genzyme Receives Positive Opinion for European Approval of Mozobil
May 21, 2009 Genzyme Submits All Information Requested by FDA for Lumizyme
May 20, 2009 Genzyme and Isis Announce that Mipomersen Phase 3 Study in Patients with Homozygous Familial Hypercholesterolemia Met Primary Endpoint
May 6, 2009 Genzyme Provides Outlook for Long-Term Growth at its Analyst Day Meeting
April 22, 2009 Genzyme Reports Solid Financial Results for the First Quarter of 2009
March 31, 2009 Genzyme and Bayer HealthCare Enter New Strategic Agreement
March 19, 2009 Genzyme Receives Positive Opinion for European Approval of Renvela for Patients with Kidney Disease
March 2, 2009 Genzyme Receives Complete Response Letter from FDA on Lumizyme Application
February 26, 2009 European Authorities Approve Larger-Scale Production of Genzyme’s Myozyme
February 26, 2009 FDA Approves Genzyme’s Synvisc-One for Osteoarthritis of the Knee
February 20, 2009 Study of Genzyme Oral Compound for Gaucher Disease Meets Primary Endpoint
February 19, 2009 Genzyme Receives Positive Opinion on Myozyme from CHMP
February 11, 2009 Strong Fourth Quarter for Genzyme Concludes Productive Year
February 3, 2009 Genzyme Center Wins Prestigious Architecture Award
January 13, 2009 Genzyme Reports Strong Fourth-Quarter and 2008 Revenue Growth
January 12, 2009 Genzyme and Isis Begin New Clinical Trials of Mipomersen
January 7, 2009 Genzyme to Present at 27th Annual JPMorgan Healthcare Conference
December 15, 2008 FDA Approves Genzyme’s Mozobil
December 11, 2008 Progress by Genzyme, the Broad Institute and Medicines for Malaria Ventures Toward Developing Drug Candidates for Malaria Highlighted at Tropical Medicine Meeting
December 9, 2008 FDA Advisory Committee Unanimously Recommends Approval of Genzyme’s Synvisc-One
December 8, 2008 Genzyme Reports Clolar® Data Further Supporting Potential of Product to Treat Adult AML Patients
December 5, 2008 FDA Advisory Committee to Discuss Genzyme’s Synvisc-One PMA on Tuesday
November 24, 2008 Genzyme Seeks U.S. Approval for Clolar® to Treat Adult AML
October 15, 2008 Genzyme Begins Enrollment in Post-Marketing Study to Evaluate Use of Low Dose Fabrazyme Treatment for Fabry Disease
September 23, 2008 Mozobil Receives Priority Review with FDA Action Expected by Year End; Synvisc-ONE FDA Action also Expected by Year End


Search News Releases

 

Terms and Conditions of Use | Privacy Policy | © 2002-2009 Genzyme Corporation. All rights reserved.